Overcoming a newly recognized form of resistance to modern prostate cancer drugs

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

masila

Rank: Vice President [?]

Points: 818 [?]

Votes: 16 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Overcoming a newly recognized form of resistance to modern prostate cancer drugs

posted on Jun 20, 2021 09:39AM

Overcoming a newly recognized form of resistance to modern prostate cancer drugs | EurekAlert! Science News

Came across this article. Seems like a few more insights into ZEN-3694 while it was being studied, especially as it relates to transcription factor E2F1.

Note the last paragraph:

Building on the findings in the current study, a larger, international, randomized clinical trial is being planned to evaluate the effectiveness of ZEN-3694 with a particular focus on men whose tumors responded poorly to androgen receptor inhibitors -- tumors that may be less dependent on the androgen receptor.